Cencora, Inc. (NYSE: COR) Shows Promising Financial Growth and Analyst Confidence

• The consensus price target for Cencora, Inc. (NYSE: COR) has increased slightly over the past year, indicating positive sentiment among analysts.
• Cencora's fiscal year 2025 second-quarter results reveal a significant revenue increase of 10.3% year-over-year and a substantial rise in diluted earnings per share (EPS) to $3.68.
• Mizuho Securities sets a price target of $162 for Cencora, reflecting confidence in the company's future growth prospects amidst challenges in the medical device sector.

Cencora, Inc. (NYSE: COR), formerly known as AmerisourceBergen Corporation, is a prominent player in the pharmaceutical distribution and healthcare solutions industry. The company provides a wide range of services and products to healthcare providers and markets. In August 2023, the company rebranded to Cencora, Inc., reflecting its evolving brand and strategic direction.

The consensus price target for Cencora's stock has shown a slight upward trend over the past year. Last month and last quarter, the average price target was $288, while a year ago, it was $277.83. This modest increase of approximately $10.17 suggests a positive sentiment or improved expectations for the company's performance. Analysts have maintained a stable outlook on Cencora's stock over the past quarter.

Cencora's fiscal year 2025 second-quarter results reveal a significant revenue increase of 10.3% year-over-year, reaching $75.5 billion. The company's diluted earnings per share (EPS) on a GAAP basis rose to $3.68, compared to $2.09 in the same quarter of the previous year. This performance highlights Cencora's strong financial growth and operational efficiency, as highlighted by Mizuho Securities.

Mizuho Securities has set a price target of $162 for Cencora, reflecting positive analyst sentiment towards the company's future prospects. The medical device sector experienced steady sales growth in the first quarter of 2025, driven by advancements in AI, wearables, and personalized care. Despite this growth, earnings gains were modest due to ongoing challenges such as global tariffs, inflationary costs, and supply chain disruptions.

Cencora is anticipated to experience growth in its earnings, as it reportedly has the right combination of factors for a potential earnings beat in its upcoming report. The company has a strong track record of surpassing earnings expectations, and it appears poised to do so again in its upcoming quarterly report. Investors are advised to prepare for the key expectations surrounding Cencora's performance.

Analysts at RBC Capital provided their views on CoreSite Realty Corporation (NYSE:COR) post Q3 results. The analysts raised their price target to $170 from $136, maintaining their sector perform rating.

Q3 results were mostly in line with expectations, with maintained 2021 guidance for revenue, EBITDA, FFO/share and lowered capex guidance by $60 million. On November 15, American Tower made an announcement, according to which it has entered into an agreement to acquire CoreSite Realty for $170 per share in an all-cash offer, with AMT the surviving entity. The value of the transaction is around $10 billion, and it is expected to close by the end of 2021.

Analysts at RBC Capital provided their views on CoreSite Realty Corporation (NYSE:COR) post Q3 results. The analysts raised their price target to $170 from $136, maintaining their sector perform rating.

Q3 results were mostly in line with expectations, with maintained 2021 guidance for revenue, EBITDA, FFO/share and lowered capex guidance by $60 million. On November 15, American Tower made an announcement, according to which it has entered into an agreement to acquire CoreSite Realty for $170 per share in an all-cash offer, with AMT the surviving entity. The value of the transaction is around $10 billion, and it is expected to close by the end of 2021.